{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T18:29:16Z","timestamp":1785176956168,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T00:00:00Z","timestamp":1752969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T00:00:00Z","timestamp":1752969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Shenzhen Key Medical Discipline Construction Fund","award":["SZXK009"],"award-info":[{"award-number":["SZXK009"]}]},{"name":"Shenzhen Sanming project","award":["SZSM202211013"],"award-info":[{"award-number":["SZSM202211013"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10157-025-02731-7","type":"journal-article","created":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T13:02:05Z","timestamp":1753016525000},"page":"1783-1795","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical outcomes of immunosuppressive therapy in patients with seronegative anti-PLA2R antibodies and PLA2R-related membranous nephropathy"],"prefix":"10.1007","volume":"29","author":[{"given":"Di","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haofei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5039-4015","authenticated-orcid":false,"given":"Qijun","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,20]]},"reference":[{"key":"2731_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/biom11040513","author":"Y Gu","year":"2021","unstructured":"Gu Y, Xu H, Tang D. Mechanisms of primary membranous nephropathy. Biomolecules. 2021. https:\/\/doi.org\/10.3390\/biom11040513.","journal-title":"Biomolecules"},{"issue":"1","key":"2731_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","volume":"361","author":"LH Beck","year":"2009","unstructured":"Beck LH, Bonegio RGB, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa0810457.","journal-title":"N Engl J Med"},{"issue":"5","key":"2731_CR3","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1111\/ajt.13133","volume":"15","author":"A Kattah","year":"2015","unstructured":"Kattah A, Ayalon R, Beck LH, Sethi S, Sandor DG, Cosio FG, Gandhi MJ, Lorenz EC, Salant DJ, Fervenza FC. Anti-phospholipase A2 receptor antibodies in recurrent membranous nephropathy. Am J Transpl. 2015;15(5):1349\u201359. https:\/\/doi.org\/10.1111\/ajt.13133.","journal-title":"Am J Transpl"},{"issue":"5","key":"2731_CR4","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/ki.2012.486","volume":"83","author":"D Kanigicherla","year":"2013","unstructured":"Kanigicherla D, Gummadova J, McKenzie EA, Roberts SA, Harris S, Nikam M, Poulton K, McWilliam L, Short CD, Venning M, et al. Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int. 2013;83(5):940\u20138. https:\/\/doi.org\/10.1038\/ki.2012.486.","journal-title":"Kidney Int"},{"issue":"6","key":"2731_CR5","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1681\/asn.2010090967","volume":"22","author":"W Qin","year":"2011","unstructured":"Qin W, Beck LH, Zeng C, Chen Z, Li S, Zuo K, Salant DJ, Liu Z. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol. 2011;22(6):1137\u201343. https:\/\/doi.org\/10.1681\/asn.2010090967.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"2731_CR6","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.2215\/CJN.07210810","volume":"6","author":"JM Hofstra","year":"2011","unstructured":"Hofstra JM, Beck LH Jr, Beck DM, Wetzels JF, Salant DJ. Anti-phospholipase A(2) receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2011;6(6):1286\u201391. https:\/\/doi.org\/10.2215\/CJN.07210810.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"2731_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/ckj\/sfy005","volume":"12","author":"LM Rodas","year":"2019","unstructured":"Rodas LM, Matas-Garcia A, Barros X, Blasco M, Vinas O, Llobell A, Martin N, Quintana LF. Antiphospholipase 2 receptor antibody levels to predict complete spontaneous remission in primary membranous nephropathy. Clin Kidney J. 2019;12(1):36\u201341. https:\/\/doi.org\/10.1093\/ckj\/sfy005.","journal-title":"Clin Kidney J"},{"issue":"1","key":"2731_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/ckj\/sfy079","volume":"12","author":"M Diaz","year":"2019","unstructured":"Diaz M, Agraz I, Soler MJ. Anti-phospholipase A2 receptor antibody and spontaneous remission in membranous nephropathy. Clin Kidney J. 2019;12(1):33\u20135. https:\/\/doi.org\/10.1093\/ckj\/sfy079.","journal-title":"Clin Kidney J"},{"issue":"4","key":"2731_CR9","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1681\/ASN.2009080861","volume":"21","author":"N Polanco","year":"2010","unstructured":"Polanco N, Gutierrez E, Covarsi A, Ariza F, Carreno A, Vigil A, Baltar J, Fernandez-Fresnedo G, Martin C, Pons S, et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol. 2010;21(4):697\u2013704. https:\/\/doi.org\/10.1681\/ASN.2009080861.","journal-title":"J Am Soc Nephrol"},{"key":"2731_CR10","unstructured":"KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases [https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34556256]"},{"issue":"11","key":"2731_CR11","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1093\/ndt\/gfv228","volume":"30","author":"E Hoxha","year":"2015","unstructured":"Hoxha E, Harendza S, Pinnschmidt HO, Tomas NM, Helmchen U, Panzer U, Stahl RA. Spontaneous remission of proteinuria is a frequent event in phospholipase A2 receptor antibody-negative patients with membranous nephropathy. Nephrol Dial Transplant. 2015;30(11):1862\u20139. https:\/\/doi.org\/10.1093\/ndt\/gfv228.","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"2731_CR12","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1111\/imj.13233","volume":"46","author":"H Liu","year":"2016","unstructured":"Liu H, Luo W, Gong S, Ding X. Detection and clinical significance of glomerular M-type phospholipase A(2) receptor in patients with idiopathic membranous nephropathy. Intern Med J. 2016;46(11):1318\u201322. https:\/\/doi.org\/10.1111\/imj.13233.","journal-title":"Intern Med J"},{"issue":"9","key":"2731_CR13","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nrneph.2017.92","volume":"13","author":"P Ruggenenti","year":"2017","unstructured":"Ruggenenti P, Fervenza FC, Remuzzi G. Treatment of membranous nephropathy: time for a paradigm shift. Nat Rev Nephrol. 2017;13(9):563\u201379. https:\/\/doi.org\/10.1038\/nrneph.2017.92.","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"2731_CR14","doi-asserted-by":"publisher","first-page":"e62151","DOI":"10.1371\/journal.pone.0062151","volume":"8","author":"YJ Oh","year":"2013","unstructured":"Oh YJ, Yang SH, Kim DK, Kang SW, Kim YS. Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy. PLoS ONE. 2013;8(4):e62151. https:\/\/doi.org\/10.1371\/journal.pone.0062151.","journal-title":"PLoS ONE"},{"issue":"2","key":"2731_CR15","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/nep.13625","volume":"25","author":"YQ Li","year":"2020","unstructured":"Li YQ, Liu ZZ, Lin KX, Liu RH, Ni L, Liu GX, Lan HY, Shi YJ. Relationship between the status of phospholipase A2 receptor and prognosis of idiopathic membranous nephropathy. Nephrology. 2020;25(2):144\u20139. https:\/\/doi.org\/10.1111\/nep.13625.","journal-title":"Nephrology"},{"issue":"1","key":"2731_CR16","doi-asserted-by":"publisher","first-page":"2297015","DOI":"10.1080\/0886022X.2023.2297015","volume":"46","author":"X Li","year":"2024","unstructured":"Li X, Shen Y, Li Y, Ma L, Sun Q. Clinicopathological characteristics and outcomes of PLA2R related idiopathic membranous nephropathy in patients with seronegative PLA2R antibodies. Ren Fail. 2024;46(1):2297015. https:\/\/doi.org\/10.1080\/0886022X.2023.2297015.","journal-title":"Ren Fail"},{"issue":"10","key":"2731_CR17","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1681\/ASN.2012030242","volume":"23","author":"JM Hofstra","year":"2012","unstructured":"Hofstra JM, Debiec H, Short CD, Pelle T, Kleta R, Mathieson PW, Ronco P, Brenchley PE, Wetzels JF. Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J Am Soc Nephrol. 2012;23(10):1735\u201343. https:\/\/doi.org\/10.1681\/ASN.2012030242.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"2731_CR18","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1080\/0886022x.2022.2033265","volume":"44","author":"G Stefan","year":"2022","unstructured":"Stefan G, Stancu S, Zugravu A, Popa O, Zubidat D, Petre N, Mircescu G. Negative anti-phospholipase A2 receptor antibody status at three months predicts remission in primary membranous nephropathy. Renal Fail. 2022;44(1):258\u201368. https:\/\/doi.org\/10.1080\/0886022x.2022.2033265.","journal-title":"Renal Fail"},{"key":"2731_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24109051","author":"OL Kukuy","year":"2023","unstructured":"Kukuy OL, Cohen R, Gilburd B, Zeruya E, Weinstein T, Agur T, Dinour D, Beckerman P, Volkov A, Nissan J, et al. The prognostic value of anti-PLA2R antibodies levels in primary membranous nephropathy. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24109051.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2731_CR20","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/j.kint.2019.07.014","volume":"96","author":"AE van de Logt","year":"2019","unstructured":"van de Logt AE, Fresquet M, Wetzels JF, Brenchley P. The anti-PLA2R antibody in membranous nephropathy: what we know and what remains a decade after its discovery. Kidney Int. 2019;96(6):1292\u2013302. https:\/\/doi.org\/10.1016\/j.kint.2019.07.014.","journal-title":"Kidney Int"},{"issue":"2","key":"2731_CR21","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1681\/ASN.2016070776","volume":"28","author":"AS De Vriese","year":"2017","unstructured":"De Vriese AS, Glassock RJ, Nath KA, Sethi S, Fervenza FC. A proposal for a serology-based approach to membranous nephropathy. J Am Soc Nephrol. 2017;28(2):421\u201330. https:\/\/doi.org\/10.1681\/ASN.2016070776.","journal-title":"J Am Soc Nephrol"},{"key":"2731_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00303-z","author":"P Ronco","year":"2021","unstructured":"Ronco P, Beck L, Debiec H, Fervenza FC, Hou FF, Jha V, Sethi S, Tong A, Vivarelli M, Wetzels J. Membranous nephropathy. Nat Rev Dis Primers. 2021. https:\/\/doi.org\/10.1038\/s41572-021-00303-z.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"2731_CR23","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1590\/2175-8239-JBN-2023-0046en","volume":"45","author":"M Dantas","year":"2023","unstructured":"Dantas M, Silva LBB, Pontes BTM, Dos Reis MA, de Lima PSN, Moyses Neto M. Membranous nephropathy. J Bras Nefrol. 2023;45(2):229\u201343. https:\/\/doi.org\/10.1590\/2175-8239-JBN-2023-0046en.","journal-title":"J Bras Nefrol"},{"issue":"8","key":"2731_CR24","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.2215\/CJN.10471013","volume":"9","author":"AP Bech","year":"2014","unstructured":"Bech AP, Hofstra JM, Brenchley PE, Wetzels JF. Association of anti-PLA(2)R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2014;9(8):1386\u201392. https:\/\/doi.org\/10.2215\/CJN.10471013.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"2731_CR25","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1681\/asn.2017070734","volume":"29","author":"B Seitz-Polski","year":"2018","unstructured":"Seitz-Polski B, Debiec H, Rousseau A, Dahan K, Zaghrini C, Payr\u00e9 C, Esnault VLM, Lambeau G, Ronco P. Phospholipase A2 receptor 1 epitope spreading at baseline predicts reduced likelihood of remission of membranous nephropathy. J Am Soc Nephrol. 2018;29(2):401\u20138. https:\/\/doi.org\/10.1681\/asn.2017070734.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"2731_CR26","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1038\/ki.1992.374","volume":"42","author":"Y Pei","year":"1992","unstructured":"Pei Y, Cattran D, Greenwood C. Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. Kidney Int. 1992;42(4):960\u20136. https:\/\/doi.org\/10.1038\/ki.1992.374.","journal-title":"Kidney Int"},{"issue":"6","key":"2731_CR27","doi-asserted-by":"publisher","first-page":"e0158154","DOI":"10.1371\/journal.pone.0158154","volume":"11","author":"K Hihara","year":"2016","unstructured":"Hihara K, Iyoda M, Tachibana S, Iseri K, Saito T, Yamamoto Y, Suzuki T, Wada Y, Matsumoto K, Shibata T. Anti-phospholipase A2 receptor (PLA2R) antibody and glomerular PLA2R expression in japanese patients with membranous nephropathy. PLoS ONE. 2016;11(6):e0158154. https:\/\/doi.org\/10.1371\/journal.pone.0158154.","journal-title":"PLoS ONE"},{"issue":"7","key":"2731_CR28","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s41581-022-00564-1","volume":"18","author":"E Hoxha","year":"2022","unstructured":"Hoxha E, Reinhard L, Stahl RAK. Membranous nephropathy: new pathogenic mechanisms and their clinical implications. Nat Rev Nephrol. 2022;18(7):466\u201378. https:\/\/doi.org\/10.1038\/s41581-022-00564-1.","journal-title":"Nat Rev Nephrol"},{"issue":"7","key":"2731_CR29","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1056\/NEJMc1011678","volume":"364","author":"H Debiec","year":"2011","unstructured":"Debiec H, Ronco P. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N Engl J Med. 2011;364(7):689\u201390. https:\/\/doi.org\/10.1056\/NEJMc1011678.","journal-title":"N Engl J Med"},{"issue":"2","key":"2731_CR30","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.kint.2021.03.028","volume":"100","author":"GB Lerner","year":"2021","unstructured":"Lerner GB, Virmani S, Henderson JM, Francis JM, Beck LH Jr. A conceptual framework linking immunology, pathology, and clinical features in primary membranous nephropathy. Kidney Int. 2021;100(2):289\u2013300. https:\/\/doi.org\/10.1016\/j.kint.2021.03.028.","journal-title":"Kidney Int"},{"issue":"2","key":"2731_CR31","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1681\/ASN.2014050502","volume":"26","author":"M Fresquet","year":"2015","unstructured":"Fresquet M, Jowitt TA, Gummadova J, Collins R, O\u2019Cualain R, McKenzie EA, Lennon R, Brenchley PE. Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy. J Am Soc Nephrol. 2015;26(2):302\u201313. https:\/\/doi.org\/10.1681\/ASN.2014050502.","journal-title":"J Am Soc Nephrol"},{"key":"2731_CR32","doi-asserted-by":"publisher","DOI":"10.1172\/JCI140453","author":"G Haddad","year":"2021","unstructured":"Haddad G, Lorenzen JM, Ma H, de Haan N, Seeger H, Zaghrini C, Brandt S, Kolling M, Wegmann U, Kiss B, et al. Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1-associated membranous nephropathy. J Clin Invest. 2021. https:\/\/doi.org\/10.1172\/JCI140453.","journal-title":"J Clin Invest"},{"issue":"6","key":"2731_CR33","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/modpathol.2012.237","volume":"26","author":"CC Huang","year":"2013","unstructured":"Huang CC, Lehman A, Albawardi A, Satoskar A, Brodsky S, Nadasdy G, Hebert L, Rovin B, Nadasdy T. IgG subclass staining in renal biopsies with membranous glomerulonephritis indicates subclass switch during disease progression. Mod Pathol. 2013;26(6):799\u2013805. https:\/\/doi.org\/10.1038\/modpathol.2012.237.","journal-title":"Mod Pathol"},{"issue":"6","key":"2731_CR34","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1016\/j.kint.2015.12.057","volume":"89","author":"MS Ryan","year":"2016","unstructured":"Ryan MS, Satoskar AA, Nadasdy GM, Brodsky SV, Hemminger JA, Nadasdy T. Phospholipase A2 receptor staining is absent in many kidney biopsies with early-stage membranous glomerulonephritis. Kidney Int. 2016;89(6):1402\u20133. https:\/\/doi.org\/10.1016\/j.kint.2015.12.057.","journal-title":"Kidney Int"},{"issue":"5","key":"2731_CR35","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1038\/ki.2015.310","volume":"88","author":"R Ramachandran","year":"2015","unstructured":"Ramachandran R, Kumar V, Nada R, Jha V. Serial monitoring of anti-PLA2R in initial PLA2R-negative patients with primary membranous nephropathy. Kidney Int. 2015;88(5):1198\u20139. https:\/\/doi.org\/10.1038\/ki.2015.310.","journal-title":"Kidney Int"},{"issue":"6","key":"2731_CR36","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1038\/ki.2015.34","volume":"87","author":"AE van de Logt","year":"2015","unstructured":"van de Logt AE, Hofstra JM, Wetzels JF. Serum anti-PLA2R antibodies can be initially absent in idiopathic membranous nephropathy: seroconversion after prolonged follow-up. Kidney Int. 2015;87(6):1263\u20134. https:\/\/doi.org\/10.1038\/ki.2015.34.","journal-title":"Kidney Int"},{"issue":"4","key":"2731_CR37","doi-asserted-by":"publisher","first-page":"530","DOI":"10.2215\/CJN.0000000000000086","volume":"18","author":"G Fernandez-Juarez","year":"2023","unstructured":"Fernandez-Juarez G, Ronco P, Jha V. Personalized treatment of PLA2R-related membranous nephropathy. Clin J Am Soc Nephrol. 2023;18(4):530\u20132. https:\/\/doi.org\/10.2215\/CJN.0000000000000086.","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-025-02731-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-025-02731-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-025-02731-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T09:30:09Z","timestamp":1764235809000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-025-02731-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,20]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2731"],"URL":"https:\/\/doi.org\/10.1007\/s10157-025-02731-7","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,20]]},"assertion":[{"value":"26 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Since the patient data collected in this study was retrospective and had been anonymized and de-identified, the Ethics Committee of Shenzhen Second People's Hospital exempted the informed consent of the study participants, and the study was approved by the Ethics Committee of Shenzhen Second People's Hospital (Ethics number:201408186).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication is not required as the data used in this study are publicly available and anonymized.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}